Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel, Erik A; Glorieux, Francis H; Whyte, Michael P; Munns, Craig F; Ward, Leanne M; Nilsson, Ola; Simmons, Jill H; Padidela, Raja; Namba, Noriyuki; Cheong, Hae Il; Pitukcheewanont, Pisit; Sochett, Etienne; Högler, Wolfgang; Muroya, Koji; Tanaka, Hiroyuki; Gottesman, Gary S; Biggin, Andrew; Perwad, Farzana; Mao, Meng; Chen, Chao-Yin; Skrinar, Alison; San Martin, Javier; Portale, Anthony A.
; 393(10189): 2416-2427, 2019 06 15.
Artigo em Inglês | MEDLINE | ID: mdl-31104833
A genetic variant of CYP2R1 identified in a cat with type 1B vitamin D-dependent rickets: a case report.
Burosumab treatment of children with X-linked hypophosphataemic rickets.
A radiological study on intra- and extra-cranial calcifications in adults with X-linked hypophosphatemia and associations with other mineralizing enthesopathies and childhood medical treatment.
[Vitamin D dependency and its treatment].
Hypophosphatemic rickets and osteomalacia.
[Mutational analysis and prenatal diagnosis in a family affected with hypophosphatemic rickets].
Hypophosphatemic rickets: unraveling the role of FGF23.
[Genetic basis for skeletal disease. Hereditary rickets].
Burosumab Therapy in Children with X-Linked Hypophosphatemia.
A novel heterozygous mutation c.680A>G (p. N227S) in SLC34A1 gene leading to autosomal dominant hypophosphatemia: A case report.